#JPM24: Catalent touts GLP-1 manufacturing; Telix grows radiopharma capacity; Arcturus expands in Japan

Catalent’s stock $CTLT rose to the highest it’s been in three months on Tuesday after CEO Alessandro Maselli emphasized the CDMO’s big picture plan to manufacture GLP-1 drugs.

Catalent had a rocky 2023, and is turning to GLP-1 and gene therapies as…
Click here to view original post